Immuno-MRM Assays
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immuno-MRM Assays - overview
Location
-, -, US
Primary Industry
Biotechnology
About
Based in the US, Immuno-MRM Assays is a specialized proteomics platform developed by Precision Assays and now operated under CellCarta, a global contract research organization (CRO) focused on precision medicine. In May 2022, CellCarta Inc. , a portfolio company of Arsenal Capital Partners, acquired Immuno-MRM Assays from Precision Assays, LLC. Immuno-MRM Assays offer multiplexed, quantitative protein measurements using multiple reaction monitoring (MRM) mass spectrometry.
These assays utilize target-specific antibodies to detect protein fragments in complex biological samples, such as FFPE tissues and serum. The platform supports over 400 anti-peptide antibodies, with a focus on immuno-oncology and signaling pathways like ras/MAPK. It enables detection of post-translational modifications and harmonized quantification across studies, making it ideal for exploratory and regulated clinical research.
Current Investors
CellCarta Inc.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Pharmaceutical Research & Development
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Immuno-MRM Assays - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Immuno-MRM Assays | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.